SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): September 11,
2008.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in BioTime's Annual
Report on Form 10-KSB filed with the Securities and Exchange Commission. Words
such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” and similar expressions identify forward-looking
statements.
Section
7 - Regulation FD
Item
7.01 - Regulation FD Disclosure
Section
9 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated September 11, 2008
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| BIOTIME, INC. | ||
|
Date: September
11, 2008
|
By
|
s/Steven Seinberg
|
|
Chief
Financial Officer
|
||
|
Exhibit
Number
|
Description
|
|
|
Press
release dated September 11, 2008
|
Exhibit
99.1
|
BioTime,
Inc
|
1301
Harbor Bay Parkway
|
|
|
Alameda,
CA 94502
|
||
|
Tel:
510-521-3390
|
||
|
Fax:
510-521-3389
|
||
|
www.biotimeinc.com
|
||
|
www.embryome.com
|
BioTime,
Inc. Conference Call Will Discuss Its Recent Acquisition of
Stem
Cell Technology Licenses
ALAMEDA, CA, September 11, 2008 – BioTime, Inc. (OTCBB: BTIM)
announced that it will host a conference call on which its Chief Executive
Officer, Dr. Michael D. West, will discuss the opportunities presented by the
recent additions to the company’s stem cell technology
portfolio. BioTime, and its wholly owned subsidiary, Embryome
Sciences, Inc., have acquired licenses for a portfolio of stem cell technology
patents and patent applications. These licenses include technology
that allows the rapid isolation of novel highly purified embryonic progenitor
cells, technology for producing induced pluripotent stem cells (“iPS”),
embryonic stem cell differentiation technology, and other technology for the
manufacture and commercialization of human embryonic stem cell-derived cell
types and related products.
Those
wishing to participate in the conference call can do so by calling (877)
807-2294 (domestic) or (706) 679-2682 (international) using participant code
64435350 on Friday, September 12, 2008 at 10:00 A.M. Pacific Daylight Savings
Time. Those who have questions they wish to have answered on the call
may email the question by 8:00 AM PST on Friday, September 12, 2008 to
rpeabody@biotimemail.com. The text of Dr. West’s presentation will also be
made available on BioTime’s website at www.Biotimeinc.com.
About
BioTime, Inc. (BTIM.OB):
BioTime,
headquartered in Alameda, California, develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions, and technology for use in surgery, emergency trauma
treatment and other applications. BioTime's lead product Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corp. under exclusive licensing agreements.
BioTime has recently entered the field
of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical
and research products using embryonic stem cell technology. Additional
information about BioTime can be found on the web at
www.biotimeinc.com. Hextend®, PentaLyte®, HetaCool®, EmbryomicsTM, ESpyTM, ESpanTM, and EScalateTM are trademarks of BioTime,
Inc.
Forward-Looking
Statements
Statements
pertaining to future financial and/or operating results, future growth in
research, technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
BioTime,
Inc.
Judith Segall
jsegall@biotimemail.com
510-521-3390,
ext 301
To
receive ongoing BioTime corporate communications, please click on the following
link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0